Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Top Cited Papers
- 11 October 2001
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 345 (15) , 1098-1104
- https://doi.org/10.1056/nejmoa011110
Abstract
Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Approximately 147,000 patients throughout the world have received infliximab. Excess TNF-α in association with tuberculosis may cause weight loss and night sweats, yet in animal models it has a protective role in the host response to tuberculosis. There is no direct evidence of a protective role of TNF-α in patients with tuberculosis.Keywords
This publication has 35 references indexed in Scilit:
- Invasive Pulmonary Aspergillosis Associated with Infliximab TherapyNew England Journal of Medicine, 2001
- Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathologyImmunology, 2001
- Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient PatientsScience, 1998
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995
- Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problemsJAMA, 1993
- Two TNF receptorsImmunology Today, 1992
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989
- Cell death in granulomata: the role of apoptosis.Journal of Clinical Pathology, 1987
- The development of clinical tuberculosis following infection with tubercle bacilliTubercle, 1982
- Complications of long-term steroid therapy for asthmaJournal of Allergy and Clinical Immunology, 1972